
New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.

New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.

Image guidance during surgery, use of lasers and other light-based therapies for upper tract disease, and clarification of the impact of surgical modifications using high-level evidence are the major themes of minimally invasive surgery that you can expect at this year’s AUA annual meeting.

At this year’s AUA annual meeting, expect much discussion in and away from the convention center to focus on what the ACA means to urologists, the work force shortage, and scope of practice issues.

At this year's AUA annual meeting, data on some newer advanced prostate cancer drugs will shine the light on their clinical utility, according to J. Brantley Thrasher, MD, of the University of Kansas Medical Center, Kansas City.

New research on potential causes of male infertility hold key messages for urologists at this year’s AUA annual meeting, according to Craig S. Niederberger, MD, of the University of Illinois, Chicago.

At this year’s AUA annual meeting, studies from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network represent the initial drops of an expected “flood of data” in coming years, according to Philip M. Hanno, MD, MPH, of the University of Pennsylvania, Philadelphia.

The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.

As in adult urology, minimally invasive approaches continue to grow in pediatric urology, which is reflected in the research being presented at this year’s AUA annual meeting.

What many retirees often don’t realize is that the Internal Revenue Service not only limits the amount you can contribute to qualified retirement plans and IRAs while you are working, but it also tells how much you must withdraw when you’re retired.

We would recommend for best practices that the urologist reviewing treatment planning for CyberKnife include in the patient record a clear indication that the radiation oncologist’s treatment plan was reviewed in detail.

Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.

The possibility of Medicare’s sustainable growth rate formula being repealed continues to strengthen in Washington following release in February of a new report by the Congressional Budget Office that cut the estimated cost that would be incurred by nearly 50%.

A coalition that includes the American College of Radiology and the American Society for Radiation Oncology is praising a segment of President Obama’s proposed fiscal year 2014 budget recommending the exclusion of radiation therapy, advanced imaging, and therapy services from the Stark law’s in-office ancillary services (IOAS) exception.

Ureteropelvic junction (UPJ) obstruction in young children can be successfully repaired with transperitoneal laparoscopic pyeloplasty, say researchers from Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center.

Men with BPH may obtain symptomatic relief with minimally invasive prostatic artery embolization (PAE), according to results from a small, prospective study.

New research on the downstream outcomes following PSA screening may help inform individualized decisions among older men considering screening.

A recently published population-based study reinforces prior evidence from retrospective studies of the increased survival benefit of partial nephrectomy over radical nephrectomy, and suggests a cancer-specific survival benefit for nephron-sparing approaches as well.

A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.

Immediate insertion of a penile prosthesis as a treatment for acute refractory ischemic priapism resolves the acute episode of ischemic penile pain and treats the inevitable erectile dysfunction, according to a recent study.

San Diego is hosting the AUA annual meeting this year, May 4-8. This Southern California city offers a great climate in which to enjoy the outdoors while also attending the year’s preeminent urology meeting.

Drugs and devices in the pipeline from AVEO Oncology; Astellas Pharma Global Development, Inc.; Nymox Pharmaceutical Corp.; TheraVida, Inc.; and Argos Therapeutics.

Intermittent androgen deprivation therapy (ADT) may compromise survival for metastatic hormone-sensitive prostate cancer patients compared with continuous ADT, according to a recently published multicenter study.

More than half of prostate cancers detected by PSA measurement are intermediate or high risk at diagnosis, according to findings from a large, population-based study.

Shared medical appointments for kidney stone patients are more beneficial than individual appointments, according to researchers from the University of Wisconsin School of Medicine and Public Health, Madison.

Urologists share their experiences with EMR systems.

The American College of Physicians has become the latest organization to weigh in on the controversial subject of PSA screening for prostate cancer.

In this graphic, parts of the Office of the Inspector General 2013 Work Plan that might affect a urology practice are discussed.

During the upcoming #AUA2013 annual meeting, Urology Times’ editorial consultants will be interviewing urology thought leaders on a range of topics, from health policy to management of stone disease.

Active surveillance appears to be a reasonable option for older patients with small renal masses, most of which are discovered during imaging for unrelated conditions, says the author of a recent study.

Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.